Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  IGF-1 LR3 vs Follistatin 344: A Simple Research Guide

IGF-1 LR3 vs Follistatin 344: A Simple Research Guide

Jun 11, 2026 4 min Growth Factor
TL;DR
IGF-1 LR3 is a long-acting growth factor analog studied for tissue growth and metabolism. Follistatin 344 is a muscle-signaling protein researched for its role in blocking a growth-limiting hormone called myostatin. Neither has full human clinical approval for performance use, and safety data in humans remains limited.

What Are These Two Peptides, Anyway?

Both IGF-1 LR3 and Follistatin 344 are proteins — long chains of amino acids — that show up often in sports science and growth-biology research. They're not the same thing, and they don't work the same way. Let's take them one at a time.

IGF-1 LR3: The Growth Factor Analog

IGF-1 LR3 stands for Insulin-like Growth Factor 1, Long Arg3. It's a lab-engineered cousin of a natural hormone your liver makes. The key tweak: its structure makes it bind less tightly to IGF-binding proteins (the molecules that normally slow IGF-1 down), so it stays active in the body longer than the natural version.[1]

In animal research, scientists infuse it directly into fetal sheep to study how growth signals affect developing tissue. One study found that even a week-long infusion didn't reliably improve growth in fetuses that were already growth-restricted — suggesting the biology is more complicated than simply adding more IGF-1.[2] Another study noticed it temporarily suppressed insulin release during infusion, though isolated pancreatic cells seemed to recover afterward.[3] Researchers have also used it to study heart and coronary vessel development in fetal animals.[6]

Follistatin 344: The Myostatin Blocker

Follistatin 344 is a naturally occurring protein, and 344 refers to the number of amino acids in this particular form. Its main research interest: it binds and neutralizes myostatin, a hormone that puts the brakes on muscle growth. Block myostatin, and in theory, muscle-building signals run more freely.

Here's an important reality check: a doping-control laboratory tested 17 black-market Follistatin 344 products and found that only 9 of them actually contained follistatin at all. The rest contained other compounds entirely, including unrelated growth peptides.[5] This underlines how murky the supply chain is for unapproved peptides.

A 2026 sports medicine review noted that Follistatin 344 (listed as FS-344) is among several unapproved peptides marketed directly to patients, with favorable signals in animal models but very scarce rigorous human safety data.[4]

Quick Comparison: IGF-1 LR3 vs Follistatin 344

  • Primary research target: IGF-1 LR3 → tissue growth, metabolism, fetal development | Follistatin 344 → myostatin inhibition, muscle signaling
  • Mechanism: IGF-1 LR3 activates the IGF-1 receptor directly | Follistatin 344 binds and neutralizes myostatin (and other related proteins)
  • Research model: IGF-1 LR3 often studied via continuous infusion in fetal sheep | Follistatin 344 studied in muscle biology and doping-detection contexts
  • Human approval status: Neither is approved for athletic or general performance use[4]
  • Supply reliability: Follistatin 344 black-market products are frequently mislabeled or contaminated[5]
  • Production complexity: IGF-1 LR3 can be produced in yeast bioreactors with demonstrated bioactivity[1] | Follistatin 344 production is more complex and less standardized

How Do Research Doses Differ?

In animal studies, IGF-1 LR3 is typically delivered by continuous intravenous infusion, not a single injection. Fetal sheep studies have used rates around 1–7 µg per kilogram per hour over multiple days.[2][3] These are highly controlled lab conditions — not comparable to any self-administered human context.

Follistatin 344 human dosing data is essentially absent from peer-reviewed literature. The sports medicine review describes it as operating outside regulatory oversight, with no established safe dose confirmed in clinical trials.[4]

If you want to explore the published dosing ranges cited in research literature, our calculator tool can help you make sense of the numbers you'll encounter in studies.

How to Choose What to Read About

Ask yourself what biological question interests you most. If you're curious about growth signaling, metabolism, or fetal/cardiac development, the IGF-1 LR3 literature is richer and more nuanced. If you're drawn to muscle biology and myostatin pathways, Follistatin 344 research is the more relevant thread — just be aware the human evidence is thin and the supply-chain data is alarming.[5]

Either way, these compounds are research tools, not approved therapies. Reading critically — noting species, dose, and study design — is the most important skill you can bring to this topic.

Sources

  1. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. — Applied microbiology and biotechnology, 2023. PMID 37261455.
  2. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. — American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943.
  3. Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. — Journal of developmental origins of health and disease, 2023. PMID 37114757.
  4. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.), 2026. PMID 41966639.
  5. Detection of black market follistatin 344. — Drug testing and analysis, 2019. PMID 31758732.
  6. Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep. — FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. PMID 32573852.
See the dosage chart — IGF-1 LR3
A long-arginine IGF-1 analog studied for anabolic signaling.
IGF-1 LR3

FAQ

What makes IGF-1 LR3 different from regular IGF-1?
IGF-1 LR3 is an engineered analog with a modified amino acid sequence that reduces its binding to IGF-binding proteins. This means it stays active in circulation longer than natural IGF-1. Researchers use it because the extended activity makes it easier to study sustained growth signaling in animal models. It was produced with confirmed bioactivity in yeast fermentation systems in recent lab work.[1]
Is Follistatin 344 the same as natural follistatin?
Not exactly. Follistatin 344 refers to a specific 344-amino-acid isoform. Natural follistatin exists in slightly different forms in the body. Black-market versions sold as FS344 have been found to carry a synthetic 'His-tag' (a lab marker) not present in the body's own follistatin, which actually helps anti-doping labs tell them apart.[5]
Have either of these peptides been tested safely in humans?
Rigorous human clinical safety trials for both IGF-1 LR3 and Follistatin 344 in performance contexts are essentially absent from the published literature. A 2026 sports medicine review specifically flags FS-344 as an unapproved compound with favorable animal data but scarce human safety evidence and real potential for harm.[4]
Why didn't IGF-1 LR3 improve growth in the sheep study?
Researchers found that growth-restricted fetal sheep given IGF-1 LR3 did not gain more weight than controls. The authors speculated that just adding the growth signal isn't enough — the fetuses may also need adequate oxygen, glucose, and insulin to respond. It highlights that growth biology involves many interacting factors, not a single switch.[2]
For research and educational use only. Not medical advice.